- Home
- FBNC vs LQDA Comparison
FBNC vs LQDA Comparison
Compare FBNC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBNC
- LQDA
- Stock Information
- Founded
- FBNC 1934
- LQDA 2004
- Country
- FBNC United States
- LQDA United States
- Employees
- FBNC N/A
- LQDA N/A
- Industry
- FBNC Major Banks
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- FBNC Finance
- LQDA Health Care
- Exchange
- FBNC Nasdaq
- LQDA Nasdaq
- Market Cap
- FBNC 2.2B
- LQDA 2.5B
- IPO Year
- FBNC N/A
- LQDA 2018
- Fundamental
- Price
- FBNC $48.95
- LQDA $29.73
- Analyst Decision
- FBNC Buy
- LQDA Strong Buy
- Analyst Count
- FBNC 4
- LQDA 10
- Target Price
- FBNC $56.67
- LQDA $37.40
- AVG Volume (30 Days)
- FBNC 190.3K
- LQDA 2.6M
- Earning Date
- FBNC 10-22-2025
- LQDA 11-03-2025
- Dividend Yield
- FBNC 1.90%
- LQDA N/A
- EPS Growth
- FBNC N/A
- LQDA N/A
- EPS
- FBNC 2.39
- LQDA N/A
- Revenue
- FBNC $364,799,000.00
- LQDA $69,216,000.00
- Revenue This Year
- FBNC $40.17
- LQDA $424.31
- Revenue Next Year
- FBNC $12.16
- LQDA $359.32
- P/E Ratio
- FBNC $20.35
- LQDA N/A
- Revenue Growth
- FBNC 0.59
- LQDA 343.41
- 52 Week Low
- FBNC $34.50
- LQDA $9.71
- 52 Week High
- FBNC $56.45
- LQDA $30.88
- Technical
- Relative Strength Index (RSI)
- FBNC 46.52
- LQDA 66.31
- Support Level
- FBNC $47.83
- LQDA $26.40
- Resistance Level
- FBNC $50.97
- LQDA $30.88
- Average True Range (ATR)
- FBNC 1.17
- LQDA 2.16
- MACD
- FBNC -0.04
- LQDA 0.42
- Stochastic Oscillator
- FBNC 37.96
- LQDA 86.14
About FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing and investment advisory services.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.